It was reasoned that combining IFN-γ therapy with anti-PD-1 would result in synergistic effects in which IFN-γ would activate the innate immune system, while anti-PD-1 treatment would avoid PD-L1-mediated immune inhibition and enable T cell-mediated tumor clearance. The gene discussed is CD274; the disease is neoplasm.